NO20051688L - Farmasoytiske blandinger som har en modifisert baerer - Google Patents

Farmasoytiske blandinger som har en modifisert baerer

Info

Publication number
NO20051688L
NO20051688L NO20051688A NO20051688A NO20051688L NO 20051688 L NO20051688 L NO 20051688L NO 20051688 A NO20051688 A NO 20051688A NO 20051688 A NO20051688 A NO 20051688A NO 20051688 L NO20051688 L NO 20051688L
Authority
NO
Norway
Prior art keywords
preparation
liquid carrier
pharmaceutical compositions
modified carrier
host
Prior art date
Application number
NO20051688A
Other languages
English (en)
Norwegian (no)
Other versions
NO20051688D0 (no
Inventor
Susan Marie Machkovech
Niki Ann Waldron
Nancy Jean Britten
Dannette Marie Shaw
Ondrej Hendl
Alanta Lea Lary
Thomas Joseph Yellig
Original Assignee
Zoetis P&U Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=32326579&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO20051688(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Zoetis P&U Llc filed Critical Zoetis P&U Llc
Publication of NO20051688D0 publication Critical patent/NO20051688D0/no
Publication of NO20051688L publication Critical patent/NO20051688L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/545—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dermatology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Cephalosporin Compounds (AREA)
NO20051688A 2002-11-19 2005-04-05 Farmasoytiske blandinger som har en modifisert baerer NO20051688L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US42768002P 2002-11-19 2002-11-19
PCT/IB2003/005234 WO2004045646A1 (en) 2002-11-19 2003-11-17 Pharmaceutical compositions having a modified vehicle

Publications (2)

Publication Number Publication Date
NO20051688D0 NO20051688D0 (no) 2005-04-05
NO20051688L true NO20051688L (no) 2005-08-02

Family

ID=32326579

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20051688A NO20051688L (no) 2002-11-19 2005-04-05 Farmasoytiske blandinger som har en modifisert baerer

Country Status (18)

Country Link
US (1) US7659061B2 (pl)
EP (1) EP1569693B1 (pl)
JP (1) JP4656945B2 (pl)
KR (1) KR20050085037A (pl)
CN (2) CN103272243A (pl)
AR (1) AR042193A1 (pl)
AU (1) AU2003276594B2 (pl)
BR (1) BR0316310A (pl)
CA (1) CA2502025C (pl)
IL (1) IL168183A (pl)
MX (1) MXPA05005319A (pl)
NO (1) NO20051688L (pl)
NZ (1) NZ539923A (pl)
PL (1) PL377740A1 (pl)
RU (1) RU2401127C2 (pl)
TW (1) TWI267379B (pl)
WO (1) WO2004045646A1 (pl)
ZA (1) ZA200503040B (pl)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010036427A1 (en) 2008-06-17 2010-04-01 Brigham Young University Cationic steroid antimicrobial diagnostic, detection, screening and imaging methods
KR20140063616A (ko) 2011-07-20 2014-05-27 브라이엄 영 유니버시티 소수성 세라게닌 화합물 및 이를 포함하는 기구
EP2755661B1 (en) 2011-09-13 2026-08-05 Brigham Young University Compositions for treating bone diseases and broken bones
BR112014005914B1 (pt) 2011-09-13 2021-11-09 Brigham Young University Produtos para cicatrização de feridas tecidulares
US9603859B2 (en) 2011-09-13 2017-03-28 Brigham Young University Methods and products for increasing the rate of healing of tissue wounds
US9694019B2 (en) 2011-09-13 2017-07-04 Brigham Young University Compositions and methods for treating bone diseases and broken bones
EP3449900A1 (en) 2011-12-21 2019-03-06 Brigham Young University Oral care compositions
US9533063B1 (en) 2012-03-01 2017-01-03 Brigham Young University Aerosols incorporating ceragenin compounds and methods of use thereof
CA2872399C (en) 2012-05-02 2021-01-12 Brigham Young University Ceragenin particulate materials and methods for making same
CA2888259C (en) 2012-10-17 2019-05-28 Brigham Young University Treatment and prevention of mastitis
AU2014203882B2 (en) 2013-01-07 2016-06-23 Brigham Young University Methods for reducing cellular proliferation and treating certain diseases
US10568893B2 (en) 2013-03-15 2020-02-25 Brigham Young University Methods for treating inflammation, autoimmune disorders and pain
BR112015023747B1 (pt) 2013-03-15 2023-04-18 Brigham Young University Uso de um composto antimicrobiano catiônico esteroide (csa) para a preparação de uma composição para tratar, reduzir, ou prevenir inflamação aguda ou crônica e/ou dor aguda ou crônica associada com uma doença ou um sintoma de doença
US11524015B2 (en) 2013-03-15 2022-12-13 Brigham Young University Methods for treating inflammation, autoimmune disorders and pain
US9387215B2 (en) 2013-04-22 2016-07-12 Brigham Young University Animal feed including cationic cholesterol additive and related methods
US11690855B2 (en) 2013-10-17 2023-07-04 Brigham Young University Methods for treating lung infections and inflammation
US20150203527A1 (en) 2014-01-23 2015-07-23 Brigham Young University Cationic steroidal antimicrobials
CA2844321C (en) 2014-02-27 2021-03-16 Brigham Young University Cationic steroidal antimicrobial compounds
US10220045B2 (en) 2014-03-13 2019-03-05 Brigham Young University Compositions and methods for forming stabilized compositions with reduced CSA agglomeration
US9867836B2 (en) 2014-03-13 2018-01-16 Brigham Young University Lavage and/or infusion using CSA compounds for increasing fertility in a mammal
US9931350B2 (en) 2014-03-14 2018-04-03 Brigham Young University Anti-infective and osteogenic compositions and methods of use
WO2015158823A1 (de) 2014-04-16 2015-10-22 Veyx-Pharma Gmbh Veterinärpharmazeutische zusammensetzung und deren verwendung
US9686966B2 (en) 2014-04-30 2017-06-27 Brigham Young University Methods and apparatus for cleaning or disinfecting a water delivery system
US10238665B2 (en) 2014-06-26 2019-03-26 Brigham Young University Methods for treating fungal infections
US10441595B2 (en) 2014-06-26 2019-10-15 Brigham Young University Methods for treating fungal infections
US10227376B2 (en) 2014-08-22 2019-03-12 Brigham Young University Radiolabeled cationic steroid antimicrobials and diagnostic methods
US10155788B2 (en) 2014-10-07 2018-12-18 Brigham Young University Cationic steroidal antimicrobial prodrug compositions and uses thereof
US9527883B2 (en) 2015-04-22 2016-12-27 Brigham Young University Methods for the synthesis of ceragenins
US10370403B2 (en) 2015-04-22 2019-08-06 Brigham Young University Methods for the synthesis of ceragenins
US9434759B1 (en) 2015-05-18 2016-09-06 Brigham Young University Cationic steroidal antimicrobial compounds and methods of manufacturing such compounds
US10226550B2 (en) 2016-03-11 2019-03-12 Brigham Young University Cationic steroidal antimicrobial compositions for the treatment of dermal tissue
US10959433B2 (en) 2017-03-21 2021-03-30 Brigham Young University Use of cationic steroidal antimicrobials for sporicidal activity
US12186328B2 (en) 2019-05-23 2025-01-07 Brigham Young University Use of CSA compounds to stimulate stem cells and hair growth

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US110561A (en) * 1870-12-27 Improvement in children s carriages
US4297353A (en) * 1980-08-04 1981-10-27 Sandoz, Inc. Non-irritating injectable dosage forms
KR890002631B1 (ko) * 1984-10-04 1989-07-21 몬산토 캄파니 생물학적으로 활성인 소마토트로핀을 지속적으로 유리하는 조성물
US5019395A (en) * 1988-03-08 1991-05-28 Warner-Lambert Company Compositions with enhanced penetration
JP2856444B2 (ja) * 1989-07-28 1999-02-10 呉羽化学工業株式会社 ビタミンｄ▲下３▼代謝産物製剤
JP3078859B2 (ja) * 1990-02-23 2000-08-21 武田薬品工業株式会社 安定な放出制御性製剤用コーティング剤
FR2692480B1 (fr) 1992-06-22 1995-12-08 Technico Flor Sa Nouvelles compositions cosmetiques ou alimentaires renfermant du copaiba.
ATE202109T1 (de) * 1993-03-12 2001-06-15 Upjohn Co Kristallines ceftiofur (freie säure)
DE4340879A1 (de) * 1993-12-01 1995-06-08 Horst P O Dr Wolf Arzneimittel zur Behandlung der Herzinsuffizienz
ATE252894T1 (de) 1995-01-05 2003-11-15 Univ Michigan Oberflächen-modifizierte nanopartikel und verfahren für ihre herstellung und verwendung
EP0914126B1 (en) 1996-06-27 2003-08-27 Janssen Pharmaceutica N.V. Sustained release sufentanil compositions
US5736151A (en) * 1996-12-09 1998-04-07 Pharmacia & Upjohn Company Antibiotic oil suspensions
US6074657A (en) 1997-03-20 2000-06-13 Pharmacia & Upjohn Company Administration of an injectable antibiotic in the ear of an animal
AU8832301A (en) 2000-09-12 2002-03-26 Upjohn Co Pharmaceutical composition having modified carrier
AU2001288322A1 (en) * 2000-09-12 2002-03-26 Pharmacia And Upjohn Company Llc Pharmaceutical composition having specific water activity

Also Published As

Publication number Publication date
US20040170650A1 (en) 2004-09-02
KR20050085037A (ko) 2005-08-29
TWI267379B (en) 2006-12-01
JP2006514629A (ja) 2006-05-11
US7659061B2 (en) 2010-02-09
IL168183A (en) 2010-04-29
RU2005115131A (ru) 2005-10-27
AU2003276594A1 (en) 2004-06-15
CN1713923A (zh) 2005-12-28
CN103272243A (zh) 2013-09-04
NO20051688D0 (no) 2005-04-05
BR0316310A (pt) 2005-09-27
WO2004045646A1 (en) 2004-06-03
NZ539923A (en) 2007-02-23
ZA200503040B (en) 2006-09-27
CA2502025A1 (en) 2004-06-03
EP1569693B1 (en) 2016-12-28
TW200427466A (en) 2004-12-16
RU2401127C2 (ru) 2010-10-10
MXPA05005319A (es) 2005-07-25
EP1569693A1 (en) 2005-09-07
CA2502025C (en) 2013-07-02
PL377740A1 (pl) 2006-02-20
JP4656945B2 (ja) 2011-03-23
AR042193A1 (es) 2005-06-15
AU2003276594B2 (en) 2009-01-08

Similar Documents

Publication Publication Date Title
WO2019191229A8 (en) Compounds for treating huntington's disease
BRPI0417684A (pt) composto, composição farmacêutica, e, uso de um composto
WO2021262826A3 (en) 1'-cyano nucleoside analogs and uses thereof
AR045900A1 (es) Compuesto glucocorticoesteroide, composiciones farmaceuticas que los contienen y su uso para el tratamiento de trastornos inflamatorios y/o alergicos.
NO20052071L (no) Bezofuranforbindelser, preparater og metoder for behandling og forebygging av hepatitt C virale infeksjoner og relaterte sykdommer.
PE20021017A1 (es) Composicion parenteral reconstituible
SG146648A1 (en) Pharmaceutical compositions for treating premature ejaculation by pulmonary inhalation
CY1111050T1 (el) Φωσφονικα, μονοφωσφοναμιδικα, διφωσφοναμιδικα για την αγωγη των ιϊκων παθησεων
NO20064347L (no) Substituerte 1,2,3,4-tetrahydroisokinolinderivater
ATE534383T1 (de) Zusammensetzungen aus n-ä2,4-bis(1,1- dimethylethyl)-5-hydroxyphenylü-1,4-dihydro-4- oxochinolin-3-carboxamid
NO20062504L (no) Sammensetninger og doseringsformer for forbedret absorpsjon
PE20080123A1 (es) Composiciones farmaceuticas que contienen vx-950 en el tratamiento de hepatitis c
SV2004001556A (es) Preparaciones acidas de insulina con establidad mejorada
NO20062146L (no) Nukleosidforbindelser for behandling av virusinfeksjoner
WO2005069933A3 (en) Methods of treating an inflammatory-related disease
EA200301018A1 (ru) Доставляемая перорально фармацевтическая композиция, включающая активное соединение, содержащее аминосульфонильную группу (ингибитор cox-2), полиэтиленгликоль и улавливающий свободные радикалы антиоксидант
SE0100901D0 (sv) New composition
NO20080875L (no) Nye makrocykliske inhibitorer av hepatitt C virus replikasjon
NO20034660L (no) Spiropyrazolforbindelser, farmasoytiske preparater som omfatter en slik forbindelse, og anvendelse av forbindelsene for fremstilling av farmasoytiske preparater
WO2008079159A3 (en) Chemicals, compositions, and methods for treatment and prevention of orthopoxvirus infections and associated diseases
NO20054083L (no) Nye sammenkoblede triazoloner og deres anvendelse
BR0316310A (pt) Composições farmacêuticas tendo um veìculo modificado
MXPA04000891A (es) Nuevos derivados de acido vinilcarboxilico y su uso como antidiabeticos.
BRPI0410495A (pt) composição para o tratamento de uma doença inflamatória dos intestinos e uso de um antagonista de interferon tipo i para preparar um medicamento
AR038143A1 (es) Agonistas del receptor 2 del factor liberador de la corticotropina

Legal Events

Date Code Title Description
CHAD Change of the owner's name or address (par. 44 patent law, par. patentforskriften)

Owner name: ZOETIS P&U LLC, US

FC2A Withdrawal, rejection or dismissal of laid open patent application